Long-term administration of L-3,4-dihydroxyphenylalanine (levodopa), the mainstay treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of action and motor complications (dyskinesia) that dramatically affect the quality of life of patients. Levodopa-induced dyskinesias (LID) can be modeled in rats with unilateral 6-OHDA lesions via chronic administration of levodopa, which causes increasingly severe axial, limb, and orofacial abnormal involuntary movements (AIMs) over time. In previous studies, we showed that the direct activation of CB1 cannabinoid receptors alleviated rat AIMs. Interestingly, elevation of the endocannabinoid anandamide by URB597 (URB), an inhibitor of endocannabinoid catabolism, produced an anti-dyskinetic response that was only partially mediated via CB 1 receptors and required the concomitant blockade of transient receptor potential vanilloid type-1 (TRPV1) channels by capsazepine (CPZ) (Morgese et al., 2007). In this study, we showed that the stimulation of peroxisome proliferator-activated receptors (PPAR), a family of transcription factors activated by anandamide, contributes to the anti-dyskinetic effects of URB + CPZ, and that the direct activation of the PPARγ subtype by rosiglitazone (RGZ) alleviates levodopa-induced AIMs in 6-OHDA rats. AIM reduction was associated with an attenuation of levodopa-induced increase of dynorphin, zif-268, and of ERK phosphorylation in the denervated striatum. RGZ treatment did not decrease striatal levodopa and dopamine bioavailability, nor did it affect levodopa anti-parkinsonian activity. Collectively, these data indicate that PPARγ may represent a new pharmacological target for the treatment of LID.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons projecting from the substantia nigra pars compacta to the striatum, a brain region controlling the execution and planning of motor behaviors (Graybiel et al., 1994) . The dopamine precursor L-3,4-dihydroxyphenylalanine (levodopa) is still considered the mainstay therapy for PD motor symptoms. However, its long-term use causes disabling complications, collectively known as levodopa-induced dyskinesias (LID) (Rascol et al., 2003; Schrag and Quinn, 2000) , consisting of uncontrolled choreiform movements of the body that profoundly affect the patients' quality of life. Clinically, LID management remains challenging due to the relatively few pharmacological treatments available, such as the NMDA antagonists amantadine and dextromethorphan (Bonifati et al., 1994; Gottwald and Aminoff, 2011; Verhagen Metman et al., 1998) , which are limited by the development of tolerance (Thomas et al., 2004) , abuse liability, and toxic side effects (Schwartz, 2005) . On the other hand, the 5-HT 1A agonist sarizotan, which has shown anti-dyskinetic activity in pre-clinical models (Gregoire et al., 2009) , has failed in clinical trials (Goetz et al., 2008) as it worsens parkinsonian symptoms. Therefore, there is an urgent need to develop new pharmacotherapies to control LID without interfering with the beneficial (pro-motor) effects of levodopa.
LID can be modeled in rats with 6-hydroxydopamine (6-OHDA) unilateral nigro-striatal lesions via chronic administration of low doses of levodopa. In these rats, chronic levodopa induces increasingly severe axial, limb, and orofacial abnormal involuntary movements (AIMs), which have been extensively characterized by different research groups
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